Eletriptan
Eletriptan, sold under the brand name Relpax and used in the form of eletriptan hydrobromide, is a second-generation triptan medication intended for treatment of migraine headaches. It is used as an abortive medication, blocking a migraine attack which is already in progress. Eletriptan is marketed and manufactured by Pfizer Inc.
Clinical data | |
---|---|
Trade names | Relpax, Relert |
AHFS/Drugs.com | Monograph |
MedlinePlus | a603029 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 50% |
Metabolism | CYP3A4 |
Elimination half-life | 4 hours |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider | |
UNII |
|
KEGG | |
ChEBI |
|
ChEMBL |
|
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.167.337 |
Chemical and physical data | |
Formula | C22H26N2O2S |
Molar mass | 382.52 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
| |
(what is this?) (verify) |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.